Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSNA1789
- Development stage
- Preclinical
- Lead developer
- Taili Biotechnology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TSNA1789 is an immune-stimulating antibody-drug conjugate (IS-ADC) developed by Taili Biotechnology (Tyligand) using its proprietary DATIA™ platform. It is designed to treat advanced malignant tumors, particularly "cold tumors" characterized by low immune infiltration. The drug consists of a monoclonal antibody targeting tumor cell antigens conjugated to a TSN222 payload, which is a STING (Stimulator of Interferon Genes) pathway agonist. Upon delivery to the tumor microenvironment, the payload activates the STING pathway, promoting the recruitment and activation of immune cells to convert "cold" tumors into "hot" tumors. As of late 2024, TSNA1789 is in preclinical development, with an Investigational New Drug (IND) application planned for the second half of 2027.
- Other names
- anti-HER2 DATIA ADCanti-HER-2 DATIA ADCanti-HER 2 DATIA ADC
02
Targets
STING (Stimulator of interferon genes protein)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TSNA1789.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSNA1789.